- Home
- SCLXW vs OCCIN Comparison
SCLXW vs OCCIN Comparison
Compare SCLXW & OCCIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- OCCIN
- Stock Information
- Founded
- SCLXW N/A
- OCCIN N/A
- Country
- SCLXW United States
- OCCIN United States
- Employees
- SCLXW 111
- OCCIN N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- OCCIN Trusts Except Educational Religious and Charitable
- Sector
- SCLXW Health Care
- OCCIN Finance
- Exchange
- SCLXW Nasdaq
- OCCIN Nasdaq
- Market Cap
- SCLXW N/A
- OCCIN N/A
- IPO Year
- SCLXW N/A
- OCCIN N/A
- Fundamental
- Price
- SCLXW $0.46
- OCCIN $24.45
- Analyst Decision
- SCLXW
- OCCIN
- Analyst Count
- SCLXW 0
- OCCIN 0
- Target Price
- SCLXW N/A
- OCCIN N/A
- AVG Volume (30 Days)
- SCLXW 4.0K
- OCCIN N/A
- Earning Date
- SCLXW 03-07-2025
- OCCIN N/A
- Dividend Yield
- SCLXW N/A
- OCCIN N/A
- EPS Growth
- SCLXW N/A
- OCCIN N/A
- EPS
- SCLXW N/A
- OCCIN N/A
- Revenue
- SCLXW $55,152,000.00
- OCCIN N/A
- Revenue This Year
- SCLXW N/A
- OCCIN N/A
- Revenue Next Year
- SCLXW N/A
- OCCIN N/A
- P/E Ratio
- SCLXW N/A
- OCCIN N/A
- Revenue Growth
- SCLXW 22.02
- OCCIN N/A
- 52 Week Low
- SCLXW $0.18
- OCCIN N/A
- 52 Week High
- SCLXW $0.18
- OCCIN N/A
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- OCCIN 59.15
- Support Level
- SCLXW N/A
- OCCIN $24.43
- Resistance Level
- SCLXW N/A
- OCCIN $24.50
- Average True Range (ATR)
- SCLXW 0.00
- OCCIN 0.05
- MACD
- SCLXW 0.00
- OCCIN -0.01
- Stochastic Oscillator
- SCLXW 0.00
- OCCIN 65.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About OCCIN OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.